141 related articles for article (PubMed ID: 12923586)
1. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
Houissa B; Mliki ML; Abdelkafi S; Bouslama M; Zaïer M; Mahjoub T; Kortas M; Ghachem L; Yacoub S
Hamostaseologie; 2003 Aug; 23(3):144-8. PubMed ID: 12923586
[TBL] [Abstract][Full Text] [Related]
2. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
[TBL] [Abstract][Full Text] [Related]
4. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
8. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
[TBL] [Abstract][Full Text] [Related]
9. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor development in non-severe haemophilia across Europe.
Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
[TBL] [Abstract][Full Text] [Related]
12. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
Mancuso ME; Fischer K; Santagostino E; Oldenburg J; Platokouki H; Königs C; Escuriola-Ettingshausen C; Rivard GE; Cid AR; Carcao M; Ljung R; Petrini P; Altisent C; Kenet G; Liesner R; Kurnik K; Auerswald G; Chambost H; Mäkipernaa A; Molinari AC; Williams M; van den Berg HM;
Thromb Haemost; 2017 Dec; 117(12):2274-2282. PubMed ID: 29212115
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
Auerswald G; Bade A; Johne J; Haubold K; Overberg D; Masurat S; Moorthi C
Thromb Res; 2014 Nov; 134 Suppl 1():S43-7. PubMed ID: 24360932
[TBL] [Abstract][Full Text] [Related]
17. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.
Eckhardt CL; Mauser-Bunschoten EP; Peters M; Leebeek FW; van der Meer FJ; Fijnvandraat K
Br J Haematol; 2012 Jun; 157(6):747-52. PubMed ID: 22533635
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
